Tocilizumab, an IL-6R blocking antibody, is already approved for treatment of rheumatoid arthritis (59, 60) and has been successfully applied to hospitalized people with COVID-19 (61), showing its potential in dampening hyperinflammatory responses. Here, IL6R is linked to rheumatoid arthritis.